Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors

Journal of Angiogenesis Research

Volumn 2, Issue 1, 2010, Pages

  Singleton, Patrick A ^a   Mambetsariev, Nurbek ^a   Lennon, Frances E ^a   Mathew, Biji ^a   Siegler, Jessica H ^a   Moreno Vinasco, Liliana ^a   Salgia, Ravi ^a   Moss, Jonathan ^a   Garcia, Joe Gn ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 4 PHOSPHATE KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; RAPAMYCIN; TEMSIROLIMUS; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; ASSAY; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; COMPLEX FORMATION; CONSTIPATION; DRUG EFFECT; DRUG POTENTIATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

MAMMALIA;

EID: 77951760826     PISSN: None     EISSN: 20402384     Source Type: Journal    
DOI: 10.1186/2040-2384-2-5     Document Type: Article

References (48)

1. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. S Brachmann C Fritsch SM Maira C Garcia-Echeverria, Curr Opin Cell Biol 2009 21 194 8 10.1016/j.ceb.2008.12.011 19201591
2. mTOR inhibitors in the treatment of cancer. A Fasolo C Sessa, Expert Opin Investig Drugs 2008 17 1717 34 10.1517/13543784.17.11.1717 18922108
3. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. LJ Malizzia A Hsu, Clin J Oncol Nurs 2008 12 639 46 10.1188/08.CJON.639-646 18676330
4. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. RT Abraham JJ Gibbons, Clin Cancer Res 2007 13 3109 14 10.1158/1078-0432.CCR-06-2798 17545512
5. Current development of mTOR inhibitors as anticancer agents. S Faivre G Kroemer E Raymond, Nat Rev Drug Discov 2006 5 671 88 10.1038/nrd2062 16883305
6. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: Role of receptor transactivation. PA Singleton MW Lingen MJ Fekete JG Garcia J Moss, Microvasc Res 2006 72 3 11 10.1016/j.mvr.2006.04.004 16820176
7. Transactivation of sphingosine 1-phosphate receptors is essential for vascular barrier regulation. Novel role for hyaluronan and CD44 receptor family. PA Singleton SM Dudek SF Ma JGN Garcia, J Biol Chem 2006 281 34381 93 10.1074/jbc.M603680200 16963454
8. Attenuation of Vascular Permeability by Methylnaltrexone: Role of mOP-R and S1P3 Transactivation. PA Singleton L Moreno-Vinasco S Sammani SL Wanderling J Moss JGN Garcia, Am J Respir Cell Mol Biol 2007 37 222 31 10.1165/rcmb.2006- 0327OC 17395891
9. Membrane Glycoproteins Associated with Breast Tumor Cell Progression Identified by a Lectin Affinity Approach. Y Wang X Ao H Vuong M Konanur FR Miller S Goodison DM Lubman, J Proteome Res 2008 7 4313 4325 10.1021/pr8002547 18729497
10. Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. PA Singleton JGN Garcia J Moss, Mol Cancer Ther 2008 7 1669 79 10.1158/1535-7163.MCT-07-2217 18566238
11. VEGF and inhibitors of TGFbeta type-I receptor kinase synergistically promote blood-vessel formation by inducing alpha5-integrin expression. Z Liu K Kobayashi M van Dinther SH van Heiningen G Valdimarsdottir T van Laar M Scharpfenecker CW Lowik MJ Goumans P Ten Dijke E Pardali, J Cell Sci 2009 122 3294 302 10.1242/jcs.048942 19706683
12. Drug synergism: its detection and applications. RJ Tallarida, J Pharmacol Exp Ther 2001 298 865 72 11504778
13. Targeted therapy for renal cell carcinoma: a new treatment paradigm. TE Hutson, Proc (Bayl Univ Med Cent) 2007 20 244 8 17637878
14. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. E Jacinto R Loewith A Schmidt S Lin MA Ruegg A Hall MN Hall, Nat Cell Biol 2004 6 1122 8 10.1038/ncb1183 15467718
15. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. DD Sarbassov SM Ali DH Kim DA Guertin RR Latek H Erdjument-Bromage P Tempst DM Sabatini, Curr Biol 2004 14 1296 302 10.1016/j.cub.2004.06.054 15268862
16. Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. M Duval F Le Boeuf J Huot JP Gratton, Mol Biol Cell 2007 18 4659 68 10.1091/mbc.E07-05-0467 17855507
17. Signaling pathways mediating VEGF165-induced calcium transients and membrane depolarization in human endothelial cells. NS Dawson DC Zawieja MH Wu HJ Granger, Faseb J 2006 20 991 3 10.1096/fj.05-3923fje 16581961
18. Redox regulation of protein-tyrosine phosphatases. J den Hertog A Groen T van der Wijk, Arch Biochem Biophys 2005 434 11 5 10.1016/j.abb.2004.05.024 15629103
19. Protein tyrosine phosphatases and signalling. AW Stoker, J Endocrinol 2005 185 19 33 10.1677/joe.1.06069 15817824
20. Molecular design and biological activities of protein-tyrosine phosphatase inhibitors. K Umezawa M Kawakami T Watanabe, Pharmacol Ther 2003 99 15 24 10.1016/S0163-7258(03)00050-0 12804696
21. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. N Slatkin J Thomas AG Lipman G Wilson ML Boatwright C Wellman DS Zhukovsky R Stephenson R Portenoy N Stambler R Israel, J Support Oncol 2009 7 39 46 19278178
22. Methylnaltrexone for opioid-induced constipation in advanced illness. J Thomas S Karver GA Cooney BH Chamberlain CK Watt NE Slatkin Stambler AB Kremer RJ Israel, N Engl J Med 2008 358 2332 43 10.1056/NEJMoa0707377 18509120
23. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. RK Portenoy J Thomas ML Moehl Boatwright D Tran FL Galasso N Stambler CF Von Gunten RJ Israel, J Pain Symptom Manage 2008 35 458 68 10.1016/j.jpainsymman.2007.12.005 18440447
24. Methylnaltrexone (Relistor) for opioid induced constipation. Med Lett Drugs Ther 2008 50 63 4 18688204
25. Development of peripheral opioid antagonists' new insights into opioid effects. J Moss CE Rosow, Mayo Clin Proc 2008 83 1116 30 10.4065/83.10.1116 18828971
26. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. JA Garcia D Danielpour, Mol Cancer Ther 2008 7 1347 54 10.1158/1535-7163.MCT-07-2408 18566209
27. Pain Relief without Side Effects: Peripheral Opiate Antagonists. J Moss J Foss, Philadelphia: Lippincott Williams & Wilkins 2005
28. Opioid agonist-antagonist drugs in acute and chronic pain states. PJ Hoskin GW Hanks, Drugs 1991 41 326 44 10.2165/00003495-199141030-00002 1711441
29. Preclinical studies of opioids and opioid antagonists on gastrointestinal function. B Greenwood-Van Meerveld CJ Gardner PJ Little GA Hicks DL Dehaven-Hudkins, Neurogastroenterol Motil 2004 16 Suppl 2 46 53 10.1111/j.1743-3150.2004.00555.x 15357851
30. Using Oral Naloxone in Management of Opioid Bowel Dysfunction. NP Sykes, New York: Haworth Medical Press 2005
31. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. CS Yuan JF Foss M O'Connor J Osinski T Karrison J Moss MF Roizen, Jama 2000 283 367 72 10.1001/jama.283.3.367 10647800
32. Kinetics of intravenous and intramuscular morphine. DR Stanski DJ Greenblatt E Lowenstein, Clin Pharmacol Ther 1978 24 52 9 657720
33. Plasma morphine concentrations during chronic oral administration in patients with cancer pain. PB Neumann H Henriksen N Grosman CB Christensen, Pain 1982 13 247 52 10.1016/0304-3959(82)90014-8 7122112
34. Peak plasma concentrations after oral morphine: a systematic review. SL Collins CC Faura RA Moore HJ McQuay, J Pain Symptom Manage 1998 16 388 402 10.1016/S0885-3924(98)00094-3 9879164
35. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. CS Yuan H Doshan MR Charney M O'Connor T Karrison SA Maleckar RJ Israel J Moss, J Clin Pharmacol 2005 45 538 46 10.1177/0091270004273491 15831777
36. Methylnaltrexone: the answer to opioid-induced constipation? RR Cannom RJ Mason, Expert Opin Pharmacother 2009 10 1039 45 10.1517/14656560902833914 19364251
37. Drug approvals: '08 in review. Methylnaltrexone (Relistor). G Laustsen F Carrillo J Johnson C Smith, Nurse Pract 2009 34 31 10.1097/01.NPR.0000345266. 90547.be 19155882
38. Temsirolimus in patients with advanced renal cell carcinoma: an overview. S Bhatia JA Thompson, Adv Ther 2009 26 55 67 10.1007/s12325-008-0138-3 19172239
39. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. G Hudes M Carducci P Tomczak J Dutcher R Figlin A Kapoor E Staroslawska J Sosman D McDermott I Bodrogi Z Kovacevic V Lesovoy IG Schmidt-Wolf O Barbarash E Gokmen T O'Toole S Lustgarten L Moore RJ Motzer, N Engl J Med 2007 356 2271 81 10.1056/NEJMoa066838 17538086
40. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC. RA Figlin, Nat Clin Pract Oncol 2008 5 601 9 10.1038/ncponc1173 18607393
41. AKT/PKB signaling: navigating downstream. BD Manning LC Cantley, Cell 2007 129 1261 74 10.1016/j.cell.2007.06.009 17604717
42. Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass. RA Frost CH Lang, J Appl Physiol 2007 103 378 87 10.1152/japplphysiol.00089.2007 17332274
43. Endothelial contraction and monolayer hyperpermeability are regulated by Src kinase. DR Mucha CL Myers RC Schaeffer Jr, Am J Physiol Heart Circ Physiol 2003 284 994 H1002 12456392
44. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. S Weis J Cui L Barnes D Cheresh, J Cell Biol 2004 167 223 9 10.1083/jcb.200408130 15504909
45. Regulation of Akt/PKB activation by tyrosine phosphorylation. R Chen O Kim J Yang K Sato KM Eisenmann J McCarthy H Chen Y Qiu, J Biol Chem 2001 276 31858 62 10.1074/jbc.C100271200 11445557
46. Protein tyrosine phosphatase 1B inhibition: opportunities and challenges. G Liu, Curr Med Chem 2003 10 1407 21 10.2174/0929867033457296 12871138
47. Dephostatin, a novel protein tyrosine phosphatase inhibitor produced by Streptomyces. II. Structure determination. H Kakeya M Imoto Y Takahashi H Naganawa T Takeuchi K Umezawa, J Antibiot (Tokyo) 1993 46 1716 9 8270494
48. Potentiation of insulin-related signal transduction by a novel protein-tyrosine phosphatase inhibitor, Et-3,4-dephostatin, on cultured 3T3-L1 adipocytes. T Suzuki A Hiroki T Watanabe T Yamashita I Takei K Umezawa, J Biol Chem 2001 276 27511 8 10.1074/jbc.M011726200 11342532